Thus, potential cardiovascular benefits of DPP‐4 inhibitors must await further investigations with appropriate surrogate markers, such as intima‐media thickening15; novel DPP‐4 inhibitors‐associated adverse events, such as bullous pemphigoid, must be carefully examined using large clinical databases16. Here, DPP4 is linked to bullous pemphigoid.